Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This study is a multicenter, randomized, double-blind, parallel-arm, Phase 3 study designed to compare efficacy, safety, immunogenicity, and PK of BAT2206 with Stelara in patients with moderate to severe plaque psoriasis. The study is composed of a ≤ 28-day screening period, a 16-week initial treatment period (TP1), a 24-week secondary treatment period (TP2), a 12-week efficacy and safety follow-up period up to end-of-study visit, for a maximum total study duration of 56 weeks.
Epistemonikos ID: 275aa27962a0b79ebe8f2c35f0b7d574b48f9486
First added on: May 08, 2024